GALECTIN THERAPEUTICS INC
Close on Oct 19, 2026
- Market cap
- $230.23M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 13, 2026, before market open (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 14, 2026 | Before market open | – | $-0.14 | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | Before market open | – | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 31, 2026 | Before market open | – | – | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 14, 2025 | Before market open | – | $-0.13 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 14, 2025 | Before market open | – | $-0.12 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 15, 2025 | Before market open | – | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | Before market open | – | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | $-0.18 | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 13, 2024 | Before market open | – | $-0.20 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 15, 2024 | Before market open | – | $-0.19 | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 29, 2024 | Before market open | – | – | – |
Press releases
Announcements Galectin Therapeutics filed with the SEC
Galectin Therapeutics Reports June 30, 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Announces Positive Type C Meeting with the FDA for Belapectin in Patients with MASH Cirrhosis and Portal Hypertension
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports March 31, 2026 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports 2025 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Since I became President and CEO of Galectin Therapeutics, I can honestly say that I have never been as excited as I am today, nor have I had the luxury of sharing such an
Regulation FD disclosure · EX-99.1 to Form 8-K
Therapeutics Reports Financial Results for the quarter ended September 30, 2025, and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Presented NAVIGATE Trial Results at the American Association for the Study of Liver Diseases (AASLD) 2025 Annual Meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the quarter ended June 30, 2025 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Belapectin for MASH Cirrhosis and Portal Hypertension June 2025
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
others. They are based on our current expectations and are subject to factors and uncertainties that could cause actual results to differ materially from those described in the statements.These statements include those regarding potential
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Galectin Therapeutics Presented NAVIGATE Trial Results at the European Association for the Study of the Liver (EASL) 2025 Congress
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Galectin Therapeutics Reports 2024 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Significant Reduction in New Varices with Belapectin in U.S. Patient Population from the NAVIGATE Trial
Other events · EX-99.1 to Form 8-K
Thank you, Kevin, and thank you to everyone for joining the call this morning. Please note that certain
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2024 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2024 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2024 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports 2023 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Thanks Kevin and thank you to everyone joining us today. Please note that certain statements made today are forward looking in nature. Please see the
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K/A
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2023 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2023 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2023 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports 2022 Financial Results and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Provides Final Randomization Status of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of Belapectin
Other events · EX-99.1 to Form 8-K
Galectin Therapeutics Announces the End of Enrollment of NAVIGATE, its Seamless, Adaptive Phase 2b/3 Study of
Other events · EX-99.1 to Form 8-K
Thanks Kevin, and thank you to everyone joining us today. Out of an abundance of caution, management and the Board made the decision to hold our meeting
Regulation FD disclosure · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended September 30, 2022 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Receives FDA Approval to Proceed with Combination Immunotherapy Trial in Head and Neck Cancer
Other events · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended June 30, 2022 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K
Galectin Therapeutics Reports Financial Results for the Quarter Ended March 31, 2022 and Provides Business Update
Results of operations · EX-99.1 to Form 8-K